Berenberg Bank Reiterates “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ($1.75) price target on the biopharmaceutical company’s stock. Berenberg Bank’s target price points to a potential downside of 98.69% from the company’s current price.

Several other brokerages have also recently issued reports on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($174.65) price target on shares of AstraZeneca in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of GBX 7,935.67 ($99.00).

AstraZeneca Price Performance

LON AZN opened at £106.68 ($133.08) on Monday. The stock’s fifty day moving average price is £105.13 and its 200 day moving average price is £116.82. AstraZeneca has a 1 year low of GBX 9,461 ($118.03) and a 1 year high of £133.88 ($167.02). The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market cap of £165.35 billion, a price-to-earnings ratio of 3,386.67, a PEG ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot purchased 20,000 shares of AstraZeneca stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average price of £102.03 ($127.28) per share, with a total value of £2,040,600 ($2,545,658.68). Also, insider Tony Mok acquired 1,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of £126.80 ($158.18) per share, for a total transaction of £190,200 ($237,275.45). 0.04% of the stock is currently owned by corporate insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.